Provided by Tiger Fintech (Singapore) Pte. Ltd.

Y-mAbs Therapeutics, Inc.

4.33
+0.02000.46%
Post-market: 4.330.00000.00%16:04 EDT
Volume:127.76K
Turnover:558.13K
Market Cap:196.13M
PE:-6.84
High:4.50
Open:4.39
Low:4.30
Close:4.31
Loading ...

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

Zacks
·
29 Apr

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

TIPRANKS
·
28 Apr

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
28 Apr

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
27 Apr

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform

TIPRANKS
·
25 Apr

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

GlobeNewswire
·
25 Apr

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
03 Apr

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates

Simply Wall St.
·
09 Mar

Y-Mabs Therapeutics (YMAB) Gets a Buy from Oppenheimer

TIPRANKS
·
05 Mar

Y-mAbs Therapeutics Inc : Truist Securities Cuts Target Price to $18 From $21

THOMSON REUTERS
·
05 Mar

Y-mAbs Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
05 Mar

Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...

GuruFocus.com
·
05 Mar

Q4 2024 Y-mAbs Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

BRIEF-Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer

Reuters
·
05 Mar

Y-mAbs Therapeutics Inc - Enters Equity Distribution Agreement With Oppenheimer

THOMSON REUTERS
·
05 Mar

Y-mAbs Therapeutics Inc - to Sell Common Stock up to $35 Million

THOMSON REUTERS
·
05 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth

Reuters
·
05 Mar

Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating

MT Newswires Live
·
05 Mar

BUZZ-Y-mAbs Therapeutics falls following gloomy 2025 revenue forecast

Reuters
·
05 Mar

Y-mAbs Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Mar